ClinicalTrials.gg
Active, not recruitingNCT07216482Updated Sep 1, 2026

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

A Phase 3 interventional study of Enlicitide and Rosuvastatin in Hyperlipidemia, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 87 sites in 11 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
996
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing rosuvastatin in Hyperlipidemias — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Hyperlipidemias.

Enrollment
2nd of 30
996 · median 114
Started
2025
with 1 other
Phase 3
7 of 30
none open now
Registered
30th of 30
by date

Among the 30 studies testing rosuvastatin in Hyperlipidemias, this one is the 2nd largest by enrollment, is one of 2 that started in 2025, is one of 7 in phase 3, and was the 30th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

1 of the 30 studies testing rosuvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing rosuvastatin in Hyperlipidemias, or all of them as a file.
02

Study summary

Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C.

The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Has either not received lipid-lowering therapy (LLT) or has not received certain LLTs within a specified time period prior to the study.

Exclusion criteria

Exclusion Criteria:

  • Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH.
  • Had a heart failure hospitalization within 3 months before Screening.
  • Is unwilling to take a statin, and/or has a history of statin-associated muscle symptoms or other statin-related AEs to any statin and dose, and/or is known to be intolerant to 1 or more statins.
  • Has a history of any of the following conditions: (1) Myopathy, myositis, rhabdomyolysis, or unexplained muscle pain; (2) Muscular or neuromuscular disease; (3) Neuropathy, fibromyalgia, or chronic pain; or (4) Has a personal or family history of hereditary muscular disorders.
  • Has active or chronic hepatobiliary or hepatic disease.
  • Has known (HIV) infection.
  • Is undergoing or previously underwent an LDL-C apheresis program within 3 months before Screening or plans to initiate an LDL-C apheresis program.
  • Has received any medication that may interact with rosuvastatin within 5 half-lives prior to Screening or is planning to initiate such treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
996 participants (actual)

Study arms

  • Experimental
    Enlicitide

    Participants will receive enlicitide and a rosuvastatin-matching placebo. Both will be delivered orally once daily (QD) for up to 12 weeks.

    Drug: Enlicitide · Drug: Placebo for Rosuvastatin

  • Experimental
    Enlicitide + Rosuvastatin

    Participants will receive enlicitide and rosuvastatin. Both will be delivered orally QD for up to 12 weeks.

    Drug: Enlicitide · Drug: Rosuvastatin

  • Active comparator
    Rosuvastatin

    Participants will receive rosuvastatin and an enlicitide-matching placebo. Both will be delivered orally QD for up to 12 weeks.

    Drug: Rosuvastatin · Drug: Placebo for Enlicitide

  • Placebo comparator
    Placebo

    Participants will receive an enlicitide-matching placebo and a rosuvastatin-matching placebo. Placebos will be delivered orally QD for up to 12 weeks.

    Drug: Placebo for Enlicitide · Drug: Placebo for Rosuvastatin

Interventions

  • Oral Tablet

    Also known as: MK-0616, Enlicitide decanoate

  • Oral Capsule

  • DrugPlacebo for Enlicitide

    Oral Tablet

  • DrugPlacebo for Rosuvastatin

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Mean Percent Change from Baseline in LDL-C at Week 8 (Enlicitide + Rosuvastatin Versus Placebo)

    Blood samples will be collected at baseline and at Week 8 to assess mean percent change in LDL-C between participants treated with enlicitide and rosuvastatin versus placebo.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Mean Percent Change from Baseline in LDL-C at Week 8

    Blood samples will be collected at baseline and at Week 8 to assess mean percent change in LDL-C.

    Time frame: Baseline and Week 8

  2. Mean Percent Change from Baseline in Apolipoprotein B (ApoB) at Week 8

    Blood samples will be collected at baseline and at Week 8 to assess mean percent change in ApoB.

    Time frame: Baseline and Week 8

  3. Number of Participants with One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 20 weeks

  4. Number of Participants who Discontinue Study Drug Due to One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 12 weeks

  5. Mean Percent Change from Baseline in LDL-C at Week 12

    Blood samples will be collected at baseline and at Week 12 to assess mean percent change in LDL-C.

    Time frame: Baseline and Week 12

  6. Mean Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) at Week 8

    Blood samples will be collected at baseline and at Week 8 to assess mean percent change in non-HDL-C.

    Time frame: Baseline and Week 8

  7. Percent Change from Baseline in Lipoprotein (a) (Lp[a]) at Week 8

    Blood samples will be collected at baseline and at Week 8 to assess percent change in Lp(a).

    Time frame: Baseline and Week 8

  8. Percentage of Participants with LDL-C <70 mg/dL and ≥50% Reduction from Baseline at Week 8

    Blood samples will be collected at baseline and at Week 8 to assess the percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline.

    Time frame: Baseline and Week 8

  9. Percentage of Participants with LDL-C <55 mg/dL and ≥50% Reduction from Baseline at Week 8

    Blood samples will be collected at baseline and at Week 8 to assess the percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline.

    Time frame: Baseline and Week 8

07

Study locations

87 sites
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Aug 2026, 8 months.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2025
First posted
Oct 14, 2025
StartActual
Nov 11, 2025
Primary completionActual
Aug 3, 2026
CompletionEst.
Nov 5, 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07216482
Responsible party
Sponsor
First posted
Oct 14, 2025
Start date
Nov 11, 2025
Primary completion
Aug 3, 2026
Completion
Nov 5, 2026 (estimated)
Last update
Sep 1, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enlicitide · Rosuvastatin

Start the discussion